Technology ID

A Novel Thermal Method to Inactivate Rotavirus for Use in Vaccines

Lead Inventor
Jiang, Baoming (CDC)
Glass, Roger (CDC)
Saluzzo, Jean-Francois (CDC)
Therapeutic Areas
Infectious Disease
Rotavirus is a highly contagious, diarrhea-inducing pathogen that annually causes approximately 250,000 deaths worldwide and millions of hospitalizations, especially afflicting infants and young children. One strategy to combat this virus is through vaccination. Continuing safety and efficacy concerns with the currently existing live, oral vaccines against rotavirus have led researchers to search for alternative treatment approaches, such as vaccines containing inactivated rotavirus.

This technology describes a method for inactivating rotavirus. Traditional inactivation strategies use chemicals that reduce antigenicity (by altering rotavirus proteins), leading to less protection against the virus. Conversely, this method preserves and/or maintains the integrity of viral particles, leading to greater protection against rotavirus. This strategy has been validated in mice, piglets and cattle and further clinical studies are underway.
Commercial Applications
  • An inactivated rotavirus virus vaccine
  • Can inactivate potential adventitious agents that might contaminate vaccines
Competitive Advantages
  • Animal studies thus far show greater protection against rotavirus than currently available vaccines
  • No formalin or beta-propiolactone required for inactivation of rotavirus
  • Greater antigenicity of treated particles compared to chemically treated particles
  • Technique preserves and maintains integrity of virus particles
Licensing Contact:
Motley, Jonathan
Phone: 301-496-2644